v3.25.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash Flows from Operating Activities    
Net loss $ (34,327,788) $ (46,833,186)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 7,154,149 6,474,256
Noncash lease expense 351,226 514,665
Stock-based compensation 1,033,718 2,628,276
Unrealized gain on short-term investments (999) (123,019)
Loss on disposal of equipment 563,865  
Loss on extinguishment 560,000  
Loss on impairment of long-lived assets 1,939,246  
Change in fair value of related party receivable 330,000  
Change in fair value of contingent earn-out receivable, related party (1,190,000)  
Change in fair value of convertible promissory notes, related party (280,950)  
Change in fair value of non-convertible promissory notes, related party 19,000  
Change in fair value of warrant liability (469,800)  
Change in fair value of contingent consideration   (107,355)
Payment of contingent consideration   (1,073,145)
Goodwill impairment loss   3,873,079
Intangible asset impairment loss   2,277,921
Amortization of intangible asset   1,091,250
Gain on sale of discontinued operations   (1,467,451)
Deferred tax liability   (571,120)
(Increase) decrease in:    
Accounts receivable 232,911 (293,698)
Prepaid expenses and other current assets (763,560) 2,731,454
Inventory 710,470 (909,158)
Other assets   (368,124)
Right-of-use assets   (277,807)
Deposits (20,334) 42,439
Grant receivable   1,524,522
Income tax receivable   600,877
Accounts payable (882,427) (116,908)
Deferred revenue (923,347) 771,133
Accrued expenses and other liabilities (42,021) (1,921,496)
Net Cash Used In Operating Activities (26,006,641) (31,532,595)
Cash Flows from Investing Activities    
Purchase of short-term investments (935,639) (483,497)
Proceeds from sale of short-term investments 3,008,050 34,237,270
Purchases of property and equipment (875,155) (1,985,557)
Proceeds from disposal of property and equipment 16,914 220,802
Proceeds from sale of Elusys Therapeutics   247,577
Net Cash Provided by Investing Activities 1,214,170 32,236,595
Cash Flows from Financing Activities    
Proceeds from December 2024 Offering 3,324,723  
Repayments of principal under finance lease (898,774) (2,583,583)
Proceeds from issuance of common stock 22,006,353 65,624
Stock issuance costs (2,219,463)  
Proceeds from issuance of convertible promissory note, related party 2,253,750  
Proceeds from issuance of non-convertible promissory notes, related party 975,000  
Proceeds from issuance of common stock through at-the-market 8,053  
Proceeds from issuance of common stock upon exercise of warrants 178,392  
Proceeds from issuance of common stock under ESPP 12,904  
Payment of contingent consideration   (6,434,115)
Cash paid for fractional shares in connection with reverse stock split (4,582)  
Net Cash Provided by (Used In) Financing Activities 25,636,356 (8,952,074)
Effect of exchange rate changes on cash and cash equivalents (813) (1,555)
Net Increase (Decrease) in Cash and Cash Equivalents 843,072 (8,249,629)
Cash and Cash Equivalents - Beginning of the Period 184,925 8,434,554
Cash and Cash Equivalents - End of the Period 1,027,997 184,925
Supplemental Disclosure for Cash Flow Information:    
Right-of-use assets surrendered upon operating lease modifications (91,890)  
Right-of-use assets obtained upon operating lease commencements   895,578
Right-of-use assets obtained upon operating lease modifications   87,839
Right-of-use assets surrendered upon finance lease modifications   (3,092,408)
Right-of-use assets obtained upon finance lease commencements   9,983,504
Right-of-use assets obtained upon finance lease modifications   $ 70,033
Supplemental disclosure of non-cash investing and financing activities:    
Reclassification of contingent earn-out receivable, related party to related party receivable $ 1,430,000  

Source

HTML PDF
ZIP